CureVac Shareholders Face Final Deadline in BioNTech Takeover

Time is running out for investors in CureVac as the company’s independence draws to a close. The German biopharmaceutical firm, once celebrated as a promising contender in the global vaccine race, is now being fully integrated into its Mainz-based competitor BioNTech. Shareholders have only days remaining to participate in the acquisition before the company’s stock is delisted from public markets.

Acquisition Terms and Critical Timeline

The transaction is structured as a pure share exchange, with CureVac stockholders receiving 0.05363 BioNTech shares for each of their current holdings. Market participants should note two crucial dates in this process:

• Tuesday, December 2, 2025 (6:00 PM Eastern Time): The operational cutoff for tendering shares
• Wednesday, December 3, 2025: The official expiration of the exchange offer

Investors who miss these deadlines face the prospect of holding illiquid positions in a company that will soon disappear from public trading. Although BioNTech plans to initiate a squeeze-out procedure for remaining shareholders once it controls 95% of shares, this process could involve significant delays.

Shareholder Approval and Strategic Rationale

The path toward acquisition was formally cleared earlier this week when CureVac’s extraordinary general meeting produced a decisive outcome. An overwhelming 99.16 percent of voting shareholders endorsed the takeover bid, indicating strong market consensus that this exit represents the most logical path to preserving the value of CureVac’s technological assets.

Should investors sell immediately? Or is it worth buying CureVac?

This move comes after CureVac struggled to commercialize any products independently and recently implemented substantial restructuring measures. The agreement with BioNTech provides a strategic solution, with the acquiring company particularly interested in CureVac’s valuable mRNA platform and oncology-focused development pipeline.

Trading Dynamics and Investor Implications

CureVac’s stock has effectively lost its independent price discovery mechanism. Trading at approximately 4.76 euros, the shares now move almost exclusively in correlation with BioNTech’s stock price, dictated by the fixed exchange ratio. The minimal price difference that remains simply reflects the slight discount until the transaction’s formal completion.

This trading pattern signals that the speculative phase has concluded, leaving technical execution as the primary consideration for market participants. Most institutional and private investors are expected to complete their share exchanges before Tuesday’s deadline, according to market analysts.